Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Healthcare Reporter.
Press releases published on August 8, 2025
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
GlobeNewswire
·
August 8, 2025
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital …
Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results
GlobeNewswire
·
August 8, 2025
Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024 Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024 Q2 …
Spectral Medical Announces Second Quarter and Provides Corporate Update
GlobeNewswire
·
August 8, 2025
Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and …
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 8, 2025
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and …
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
GlobeNewswire
·
August 8, 2025
FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the potentially eligible patient pool as compared to original …
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
GlobeNewswire
·
August 8, 2025
NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory …
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
GlobeNewswire
·
August 8, 2025
Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basis Total Rare Disease quarterly net revenues of $104.0 million, which includes: Purified Cortrophin® Gel …
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
GlobeNewswire
·
August 8, 2025
Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 million SERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction …
Sanuwave Announces Q2 FY2025 Financial Results
GlobeNewswire
·
August 8, 2025
Q2 2025 revenues were $10.2 million, up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3%, versus 73.2% in Q2 2024. GAAP Operating Income was $1.9 million for Q2 2025 …
Sai Life Sciences Limited Reports Revenue growth of 77% YoY
GlobeNewswire
·
August 8, 2025
HYDERABAD, India, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research, Development and Manufacturing Organization (CRDMO) announced its financial results for the first quarter of …
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
GlobeNewswire
·
August 8, 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2025. The full report …
Nicox Extends Existing Flexible Equity Financing
GlobeNewswire
·
August 8, 2025
5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid-September 2025 August 08, 2025 – release at 7:30 am Sophia Antipolis, France Nicox SA (Euronext Growth …
Nicox étend sa ligne de financement flexible existante
GlobeNewswire
·
August 8, 2025
5 millions d’actions ajoutées à la ligne de financement en fonds propres existante avec Vester Finance Les premiers résultats de l’étude confirmatoire de Phase 3 Denali sur NCX 470 sont attendus entre mi-août et mi-septembre 2025 08 août 2025 – publication …
Public and Private Sectors Unite to Enhance Vision Care Access for Patients in Need Ahead of SG60
GlobeNewswire
·
August 8, 2025
SINGAPORE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In a move that reflects Singapore’s commitment to inclusive healthcare and smarter service delivery, the Singapore National Eye Centre (SNEC) and OneSight EssilorLuxottica Foundation have come together to …
Market Forecast News: Pressure Monitoring to Hit $25.48B by 2032 | MarketsandMarkets™.
GlobeNewswire
·
August 8, 2025
Delray Beach, FL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The global pressure monitoring market, valued at US$13.63 billion in 2024 stood at US$14.56 billion in 2025 and is projected to advance at a resilient CAGR of 8.3% from 2025 to 2032, culminating in a …
BioVie Inc. Announces Pricing of $12 Million Public Offering
GlobeNewswire
·
August 8, 2025
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and …
Heartflow, Inc. Announces Pricing of Upsized Initial Public Offering
GlobeNewswire
·
August 8, 2025
MOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its upsized initial public offering of 16,666,667 shares of its …
Specialty Enzymes Market to Reach $9.2 Billion by 2029, Driven by Biotech Innovation and Public Funding
GlobeNewswire
·
August 8, 2025
Delray Beach, FL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- According to a research report published by MarketsandMarkets, "Specialty Enzymes Market by Source (Microorganism, Plant, Animal), Type (Carbohydrases, Proteases, Lipases, Polymerases …